PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

New soy-based natural S-equol supplement reduces menopausal hot flashes, muscle and joint pain in first study among US women

Studies document improved health with natural S-equol presented at the North American Menopause Society Annual Meeting

2010-10-07
(Press-News.org) CHICAGO, IL (Oct. 6, 2010) – A new women’s health, whole soy germ-based nutritional supplement containing Natural S-equol reduced the frequency of moderate to severe hot flashes and reduced muscle and joint pain in the first study of its kind among postmenopausal U.S. women, according to peer-reviewed data presented as a poster presentation at the North American Menopause Society (NAMS) Annual Meeting. Also, the first study to report Natural S-equol contributions to bone health and a study of Natural S-equol safety were presented at NAMS. “These data from U.S. women expand our knowledge about and corroborate previous research in Japanese women about the benefit of a supplement containing the soy-based compound Natural S-equol to manage menopausal symptoms, including reducing the frequency of hot flashes and muscle discomfort. This and the other Natural S-equol studies are part of the rigorous clinical collaborative program of Pharmavite LLC and Otsuka Pharmaceutical Co., Ltd. to develop a supplement containing Natural S-equol,” said Belinda H. Jenks, Ph.D., coauthor of the US women’s and safety studies and director of Scientific Affairs & Nutrition Education at Pharmavite LLC. S-equol [7-hydroxy-3-(4’-hydroxyphenyl)-chroman] is a compound resulting -- when certain bacteria are present in the digestive tract -- from the natural metabolism, or conversion, of daidzein, an isoflavone found in whole soybeans. Not everyone can produce S-equol after soy consumption, as the production depends on the types of bacteria present in the large intestine and may be influenced by the amount of soy consumed. About 50 percent of Asians and 20 to 30 percent of North Americans and Europeans, who in general consume less soy than Asians, have the ability to produce S-equol. Research indicates that Japanese women have milder menopausal symptoms in those who are S-equol producers compared to nonproducers. S-equol selectively binds to the receptors for the naturally occurring female sex hormone estrogen, with a strong affinity to the estrogen receptor beta. On binding to these receptors, S-equol mimics some, but not all, activities of natural estrogen. Because of these actions at the receptor, it has been proposed that S-equol may alleviate some of the symptoms caused by diminished estrogen production during menopause. Natural S-equol Supplement Reduces Menopausal Hot Flashes in U.S. Women In the double-blinded study of 102 US postmenopausal women, eight weeks of daily SE5-OH supplement doses containing 10, 20 or 40 milligrams (mg) of Natural S-equol reduced the frequency of moderate to severe hot flashes as did 50 mg doses of a soy isoflavone supplement. Because isoflavones are known to have mild effects on the reduction of hot flashes in menopausal women, the investigators used an isoflavone supplement as a comparator in the study. More women in the 10, 20 and 40 mg Natural S-equol groups achieved a 50 percent or more reduction in their hot flash frequency, a primary endpoint of the study, than in the isoflavone group: respectively, 42.9 (P=0.056), 27.3, 25.0 and 16.0 percent. To enroll in the study, all of the women had to experience more than 35 hot flashes per week. The 20 mg Natural S-equol dose neared statistical superiority (P=0.076), the 10 mg dose was similar (P=0.503) and the 40 mg dose was significantly more effective than the soy isoflavones in reducing hot flash frequency (P=0.021), according to a Mixed-Effect Model Repeated Measure analysis incorporating the eight weekly reports of women’s hot flash frequency, a secondary endpoint of the study. Moreover, muscle and joint pain was reduced significantly in the 10 and 20 mg Natural S-equol groups compared to those in the isoflavone group (P< 0.05). Investigators used the validated Greene Climacteric Scale that measures 20 symptoms to produce three symptom measures: psychological, somatic (physical) and vasomotor. “Together these data document that a minimum daily dose of 10 mg Natural S-equol would provide the benefit of both reducing the frequency of moderate to severe hot flashes as well as decreasing muscle and joint pain associated with menopause,” explained Jenks. The trial also noted treatment-emergent adverse effects in participants of all the treatment groups. Such effects occurring in more than 5 percent of each group included abdominal distention, constipation and endometrial hypertrophy, the thickening of the lining of the uterus. The endometrial hypertrophy was identified by transvaginal ultrasounds and assessed by the Medical Monitor, and any changes observed were not considered to be clinically significant. No trends or clinically meaningful changes were identified in laboratory blood or urine tests, electrocardiographs, physical examinations or vital signs among the participants. The trial enrolled women aged 45 to 65 years, who had levels of follicle stimulating hormone (FSH) of 40 or more milli international units/microliter, a marker of menopause. Investigators randomized the women into four groups to receive either the isoflavone (26 women) or one of the three doses of the Natural S-equol supplement (24 in the 10 mg, 27 in the 20 mg and 25 in the 40 mg groups), in the form of daily tablets taken with breakfast and dinner meals for 12 weeks. The women had diets controlled for soy foods, isoflavone and lignans, compounds found in certain plants that are known as phytoestrogens because of their estrogen-like properties. The study included a period before the treatment weeks to allow for elimination of any women who responded to a placebo. Women also were tested to determine their ability to produce S-equol after eating soy. The study included 70 percent equol nonproducers and 30 percent equol producers. Natural S-equol Inhibits Bone Break Down, Prevents Bone Mineral Density Loss This study is the first to document evidence that daily doses of SE5-OH supplements containing 10 mg of Natural S-equol given for 12 months significantly inhibited bone break down, or resorption, in postmenopausal women. Moreover, treatment with the 10 mg Natural S-equol dose significantly prevented a decrease in whole body bone mineral density (BMD), compared to placebo. “These findings raise the possibility that 10 mg daily of Natural S-equol supplementation may contribute to bone health without adverse effects in postmenopausal women who can not make S-equol themselves after eating soy. Further research is needed to determine the effects of S-equol on bone metabolism and safety,” explains Jenks. In this one-year, double-blind, placebo-controlled study, investigators randomized 93 Japanese women to receive a placebo or one of three daily doses of SE5-OH containing Natural S-equol: 2, 6 or 10 mg. Women studied were equol nonproducers, and averaged 53.8 ± 3.7 years old and 2.7 ± 1.2 years since menopause. After 12 months, women receiving the 10 mg dose of Natural S-equol had a significantly decreased, by 23.9 percent, the amount of urinary deoxypyridinoline (DPD) for 24 hours, a validated marker for bone resorption, compared to a reduction of just 2.9 percent in the placebo group (P=0.020). In addition, the whole body BMD in the 10 mg group declined by 1.1 percent, significantly less than the 1.9 percent decrease of the placebo group (P=0.027) at 12 months. Serum sex and thyroid hormone concentrations did not differ among four groups at the study end. Safety Data from 12-Week Study of Natural S-equol Use in Japanese Women Investigators identified no safety problems, particularly in the female reproductive system, among 101 healthy Japanese postmenopausal women who took daily SE5-OH supplement doses containing 30 mg Natural S-equol for 12 weeks as part of a randomized, placebo-controlled study. The investigators found no serious adverse events, and no abnormal changes in serum concentrations of five hormones measured at the study start and weeks four, eight and 12 of the study: estradiol, follicle stimulating hormone, thyroid-stimulating hormone, free triiodothyronine (T3), and free-thyroxine (T4). Also, ultrasound measures of the thickness of the endometrial lining of the uterus and cellular studies of the tissue lining the vagina revealed no biological effect of the supplement on the women’s reproductive organs. Furthermore, mammography examination results documented no differences among the women groups or between the study start and end. The study participants were 101 healthy postmenopausal women aged 45 to 65 years who experienced the onset of menopause within the past five years prior to enrollment. None of them were S-equol producers and they were randomized to receive either 10 mg or 30 mg daily doses of Natural S-equol or a placebo. How SE5-OH is Made All three studies presented at NAMS used supplement tablets that contained Natural S-equol. The SE5-OH is the product of fermentation of whole soy germ by the bacterial strain Lactococcus 20-92 using a patented and proprietary process by the Otsuka Pharmaceutical Co., Ltd. The process results in the conversion of the daidzein to S-equol. SE5-OH is created under current Good Manufacturing Practices. Following fermentation, the bacteria undergo heat denaturation and are deactivated. The process is designed to produce a Natural S-equol rich product, or nutraceutical ingredient. The ingredient has self-affirmed GRAS (Generally Recognized As Safe) status. ### Development and ongoing research of SE5-OH containing Natural S-equol is conducted by the Saga Nutraceuticals Research Institute of Otsuka Pharmaceutical Co., Ltd. Pharmavite LLC, the makers of Nature Made® vitamins and minerals and a subsidiary of Otsuka, is studying SE5-OH containing Natural S-equol in supplement form for the management of menopausal symptoms. Otsuka Pharmaceutical Co. Ltd. supported all four studies. Complete reports of data from each study will be submitted for peer-review publication. NAMS Poster Session Thursday, Oct. 7, 2010 5:15 PM CDT (6:15 EDT)
Poster P-22 Efficacy and safety of natural S-equol supplement in US postmenopausal women
Belinda H. Jenks of Scientific Affairs, Pharmavite LLC, Northridge, CA; Shigeto Uchiyama of Saga Nutraceuticals Research Institute, Otsuka Pharmaceutical Co, Ltd., Japan; Soh Iwashita of Scientific Affairs, Pharmavite LLC, Northridge, CA; and Yasushi Nakagawa, Jennifer Lee, Dusan Kostic and Karen Ragland of Otsuka Pharmaceutical Development & Commercialization, Inc. United States. Poster P-46
Japan safety assessments of natural S-equol supplement by consecutive ingestion to postmenopausal Japanese women.
Ayuko Oyama and Tomomi Ueno of Saga Nutraceuticals Research Institute, Otsuka Pharmaceutical Co., Ltd; Belinda H. Jenks of Scientific Affairs, Pharmavite LLC, Northridge, CA, United States; and Takeshi Aso of Obstetrics and Gynecology, Tokyo Medical and Dental University, Tokyo, Japan. Poster P-79
Effect of natural S-equol on bone metabolism in equol non-producing postmenopausal Japanese women: a pilot randomized placebo-controlled trial.
Tomomi Ueno, Yasuhiro Fujii, and Shigeto Uchiyama of Saga Nutraceutricals Research Institute, Otsuka Pharmaceutical Co., Ltd.; Yuko Tousen and Junko Ezaki of Department of Nutrition, Chiba Prefectural University of Health Sciences, Chiba, Japan; Mamoru Nishimuta of Food Function and Labeling Program, National Institute of Health and Nutrition, Tokyo; and Yoshiko Ishimi of Nutritional Epidemiology Program, National Institute of Health and Nutrition, Tokyo. About Pharmavite LLC: For almost 40 years, Pharmavite has earned and maintained the trust of healthcare professionals, consumers, and retailers by manufacturing high-quality vitamins, minerals, herbs and other dietary supplements that are safe, effective and science-based. Nature Made® is the number one selling dietary supplement brand in the food, drug, club and mass channels. The dietary supplement industry is regulated by the U.S. Food and Drug Administration and the Federal Trade Commission, as well as by government agencies in each of the 50 states. About Otsuka Pharmaceutical Co., Ltd.: Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The Otsuka Group comprises 145 companies and employs approximately 39,000 people in 23 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥1,084.2 billion (approx. US $11.7 billion*) in annual revenues in fiscal 2009. Visit Otsuka Pharmaceutical Co., Ltd. at www.otsuka-global.com.


ELSE PRESS RELEASES FROM THIS DATE:

Tip sheet: Soy-based natural S-equol supplement data presented from 4 studies at the North American Menopause Society Annual Meeting

2010-10-07
Four clinical studies that add to the evidence about the use of a new nutritional supplement containing the whole soy germ-based ingredient Natural S-equol to improve health were presented at the North American Menopause Society (NAMS) Annual Meeting. These studies include a poster about a first-of-its-kind study in U.S. women that documents the effectiveness of Natural S-equol in reducing the frequency of moderate to severe hot flashes and reducing muscle and joint pain. A second poster reported the first clinical study about Natural S-equol contributions to bone health. ...

Family ties bind desert lizards in social groups

2010-10-07
SANTA CRUZ, CA-- Researchers at the University of California, Santa Cruz, have found that a species of lizard in the Mojave Desert lives in family groups and shows patterns of social behavior more commonly associated with mammals and birds. Their investigation of the formation and stability of family groups in desert night lizards (Xantusia vigilis) provides new insights into the evolution of cooperative behavior. The researchers reported the results of a five-year study of desert night lizards in a paper published in the Proceedings of the Royal Society B: Biological ...

GOES-13 on top of new seventeenth Atlantic (sub) tropical depression

GOES-13 on top of new seventeenth Atlantic (sub) tropical depression
2010-10-07
The GOES-13 satellite keeps a vigilant eye on the Atlantic Ocean and eastern U.S. and this morning at 5 a.m. EDT it saw System 97L organize into the seventeenth tropical depression of the Atlantic Ocean season. The only catch is that it is actually a subtropical depression, so it is currently known as Subtropical Depression 17 (TD17). A subtropical storm is one where central convection (rapidly rising air that forms thunderstorms) is fairly near the center and it has a warming core in the mid-levels of the troposphere. Subtropical cyclones differ from tropical cyclones ...

Skin color linked to social inequality in contemporary Mexico, study shows

2010-10-07
WASHINGTON, DC, October 6, 2010 — Despite the popular, state-sponsored ideology that denies the existence of prejudice based on racial or skin color differences in Mexico, a new study from The University of Texas at Austin provides evidence of profound social inequality by skin color. According to the study, individuals with darker skin tones have less education, have lower status jobs, are more likely to live in poverty, and are less likely to be affluent. Andrés Villarreal, an associate professor in the Department of Sociology and the Population Research Center affiliate, ...

Swedish Research Council to bar cheaters

2010-10-07
Barred for up to ten years from receiving research grants from the Swedish Research Council. There will be serious consequences for the few researchers who are guilty of plagiarism, falsification, or inventing results. "We need to be able to rely on research findings," says Pär Omling, Director General of the Swedish Research Council. The Swedish Research Council has made a decision about how it should deal with researchers who are found to have committed research fraud. Any researcher who has been vetted by a panel of experts within the Central Ethical Review Board ...

Gene therapy reveals unexpected immunity to dystrophin in patients with Duchenne muscular dystrophy

2010-10-07
An immune reaction to dystrophin, the muscle protein that is defective in patients with Duchenne muscular dystrophy, may pose a new challenge to strengthening muscles of patients with this disease, suggests a new study appearing in the October 7, 2010, issue of The New England Journal of Medicine. Duchenne muscular dystrophy (DMD) is a hereditary and lethal neuromuscular disease characterized by progressive loss of muscle strength and integrity. Genetic information important for production of a functional dystrophin protein is deleted from the DMD gene of many patients. ...

Drug that helps adults addicted to opioid drugs also relieves withdrawal symptoms in newborns

2010-10-07
(PHILADELPHIA) - Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue ...

High risk of acute mountain sickness on Mount Kilimanjaro

High risk of acute mountain sickness on Mount Kilimanjaro
2010-10-07
New Rochelle, NY, October 6, 2010 –Climbers of high peaks such as Mount Kilimanjaro are at high risk for Acute Mountain Sickness (AMS). Trekkers should not ignore AMS warning signs, which can progress to more serious medical outcomes. Mountain climbers can best minimize their risk for altitude sickness by becoming acclimatized to increased altitudes before an ascent, according to a study in the current issue of High Altitude Medicine & Biology, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article is available free online at www.liebertpub.com/ham The ...

Novel reference material to standardize gene therapy applications

Novel reference material to standardize gene therapy applications
2010-10-07
New Rochelle, NY, October 6, 2010—The introduction of a new, fully characterized viral vector for use as reference material to help standardize gene therapy protocols in research applications and human clinical trials is described in an article in Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article, which is published online ahead of print, is available free online at www.liebertpub.com/hum The growing popularity in the gene therapy community of using recombinant adeno-associated virus (rAAV) vectors as vehicles ...

Scripps Research scientists develop novel test that identifies river blindness

2010-10-07
LA JOLLA, CA – October 6, 2010 – For Immediate Release – Scientists from The Scripps Research Institute have developed the first screening method that rapidly identifies individuals with active river blindness, a parasitic disease that afflicts an estimated 37 million people. The test could change the current strategy of mass treatment in areas where river blindness, also known as onchocerciasis, is suspected. The study was published online on October 5, 2010, by the journal PLOS Neglected Tropical Diseases. "A sensitive and reproducible diagnostic test for this disease ...

LAST 30 PRESS RELEASES:

The refrigerator as a harbinger of a better life

Windfall profits from oil and gas could cover climate payments

Heartier Heinz? How scientists are learning to help tomatoes beat the heat

Breaking carbon–hydrogen bonds to make complex molecules

Sometimes you're the windshield: Utah State University researcher says vehicles cause significant bee deaths

AMS Science Preview: Turbulence & thunderstorms, heat stress, future derechos

Study of mountaineering mice sheds light on evolutionary adaptation

Geologists rewrite textbooks with new insights from the bottom of the Grand Canyon

MSU researcher develops promising new genetic breast cancer model

McCombs announces 2024 Hall of Fame inductees and rising stars

Stalling a disease that could annihilate banana production is a high-return investment in Colombia

Measurements from ‘lost’ Seaglider offer new insights into Antarctic ice melting

Grant to support new research to address alcohol-related partner violence among sexual minorities

Biodiversity change amidst disappearing human traditions

New approaches to synthesize compounds for pharmaceutical research

Cohesion through resilient democratic communities

UC Santa Cruz chemists discover new process to make biodiesel production easier, less energy intensive

MD Anderson launches Institute for Cell Therapy Discovery & Innovation to deliver transformational new therapies

New quantum encoding methods slash circuit complexity in machine learning

New research promises an unprecedented look at how psychosocial stress affects military service members’ heart health

Faster measurement of response to antibiotic treatment in sepsis patients using Dimeric HNL

Cleveland Clinic announces updated findings in preventive breast cancer vaccine study

Intergenerational effects of adversity on mind-body health: Pathways through the gut-brain axis

Watch this elephant turn a hose into a sophisticated showering tool

Chimpanzees perform better on challenging computer tasks when they have an audience

New medical AI tool identifies more cases of long COVID from patient health records

Heat waves and adverse health events among dually eligible individuals 65 years and older

Catastrophic health expenditures for in-state and out-of-state abortion care

State divorce laws, reproductive care policies, and pregnancy-associated homicide rates

Emerging roles of high-mobility group box-1 in liver disease

[Press-News.org] New soy-based natural S-equol supplement reduces menopausal hot flashes, muscle and joint pain in first study among US women
Studies document improved health with natural S-equol presented at the North American Menopause Society Annual Meeting